Contract drug services

Contract drug services provider WuXi Biologics announced on Wednesday it has raised its guidance for new projects in 2024 from 80 to 110, despite a slowdown in biotech financing, after seeing a strong recovery in demand in the second half of last year.

FAST NEWS: WuXi Biologics boosts new projects target

The latest: Contract drug services provider WuXi Biologics (Cayman) Inc. (2269.HK) announced on Wednesday it has raised its guidance for new projects in 2024 from 80 to 110, despite a…
2269.HK

Recent Articles

RELATED ARTICLES

  1. The latest draft of a U.S. biosecurity law would give drug companies until 2032 to cut their ties with Chinese contract suppliers, allowing WuXi companies time to focus on Europe instead.
    U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
    2269.HK 2359.HK 2268.HK
  2. WuXi Bio prescribes share buyback to relieve revenue pain
    2269.HK
  3. Potential U.S. targeting casts shadow over WuXi AppTec family
    2359.HK 603259.SHG
  4. WuXi AppTec posts lower profits but avoids more share price pain  
    2359.HK 603259.SHG
  5. WuXi AppTec mulls gene unit sale to soften U.S. legal blow
    2359.HK 603259.SHG
  6. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  7. China-focused Tigermed staves off biopharma gloom
    3347.HK 300347.SHE
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva